PUXTARROW — 2493085
Application number
2493085
Type(s)
Standard Characters
Category
Trademark
CIPO Status
FORMALIZED
TM5 status
LIVE/APPLICATION/
Awaiting Examination
The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.
Filed
2026-08-06
Applicant
AstraZeneca AB
SE-151
85 Södertälje,
SWEDEN
Agent
SMART & BIGGAR LP
Scotia Plaza, 40 King Street West
40th Floor
Toronto
ONTARIO M5H3Y2
Documents
Index headings
- PUXTARROW
- PUXT ARROW
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of oncologic diseases and disorders; pharmaceutical preparations and substances for use in the treatment of cardiovascular, renal, endocrine, respiratory, inflammatory, immunologic, hematological, gastrointestinal, and autoimmune diseases and disorders; pharmaceutical preparations and substances for use in the treatment of metabolic diseases and disorders, namely, cirrhosis, dyslipidaemia, metabolic dysfunction-associated steatohepatitis, chronic weight management and obesity, primary aldosteronism, transthyretin amyloid cardiomyopathy, amyloidosis with cardiac involvement, mineral metabolism diseases and disorders, metabolic bone diseases and disorders, enzyme function diseases and disorders, and diseases and disorders associated with natural substrates of alkaline phosphatase; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations and substances for use in the treatment of immune-mediated diseases and disorders, namely, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, ANCA associated vasculitis, myositis, B cell mediated autoimmune disease, Crohn's disease, inflammatory vascular diseases, and myeloproliferative disorders; pharmaceutical preparations and substances for use in the treatment of neurological and neurodegenerative diseases and disorders, namely, neuromyelitis optica spectrum disorder (NMOSD), polyneuropathy, neurofibromatosis type 1 with plexiform neurofibromas (NF1 PN), multiple system atrophy (MSA), chronic hypoparathyroidism; pharmaceutical preparations and substances for use in the treatment of infectious diseases and disorders, namely respiratory infections, gastrointestinal infections, skin infections, blood infections; vaccines for human use
Claims
- Priority Filing Date: April 01, 2026, Country or Office: EUIPO (EU), Application No. 019341358 in association with the same kind of goods
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2026-08-06 | ||
| Created | 2026-08-06 | ||
| Formalized | 2026-08-06 |